Skip to main content

Avidity Biosciences Inc News

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

The company presents at the J.P. Morgan Healthcare Conference on Thursday.

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know

To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.

Prosensa Holding (RNA) Upgraded From Sell to Hold

Prosensa Holding (RNA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

Breaking News

Elon Musk Throws Dogecoin a Lifeline

Elon Musk will soon allow Dogecoin to purchase SpaceX merchandise.

Disney Fans Angry, Excited About New Guardians of the Galaxy Ride

The theme park company has opened Guardians of the Galaxy: Cosmic Rewind and not everyone is happy despite the ride getting wonderful reviews.

Aurora Cannabis Slashing Weed Capacity in Profitability Push

Aurora is slashing its production capacity as it builds a runway toward positive Ebitda a year from now.

Costco Beats Q3 Sales Forecast, Membership Revenues Near $1 Billion

Costco took in $984 million in new membership fee in its fiscal third quarter, helping the bulk retailer top Street forecasts for topline revenues.